Weave Communications, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Weave Communications, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $239.02M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $204.31M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $170.47M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $142.12M | Mar 13, 2025 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $170.47M | Mar 13, 2024 |
| FY2023 | Dec 31, 2022 | $142.12M | Mar 13, 2024 |
| FY2023 | Dec 31, 2021 | $115.87M | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | $79.90M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $45.75M | Mar 23, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $172.31M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $145.88M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $116.09M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $88.84M | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | $66.50M | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | $45.45M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $27.23M | Mar 23, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($28.05M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($28.35M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | ($31.03M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | ($49.74M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | ($51.69M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | ($40.42M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | ($32.06M) | Mar 23, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($30.61M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($31.41M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | ($34.37M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | ($49.70M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | ($50.39M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | ($39.57M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | ($31.92M) | Mar 23, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.46M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $40.23M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $34.04M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $30.71M | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | $27.01M | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | $19.97M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $14.41M | Mar 23, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.54M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $14.15M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $10.22M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | ($12.77M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | ($20.37M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | ($15.52M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | ($22.07M) | Mar 23, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.39M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $2.19M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $1.69M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $1.90M | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | $7.38M | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | $2.76M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $2.47M | Mar 23, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $207.97M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $188.93M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $201.01M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $208.35M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $187.49M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $92.97M | Mar 23, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $125.58M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $121.96M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $122.06M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $125.13M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $75.18M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $54.98M | Mar 23, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $82.38M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $66.97M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $78.96M | Mar 5, 2026 |
| FY2025 | Dec 31, 2022 | $83.22M | Mar 5, 2026 |
| FY2024 | Dec 31, 2021 | $112.30M | Mar 13, 2025 |
| FY2023 | Dec 31, 2020 | ($113.95M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2019 | ($85.99M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2018 | ($61.92M) | Mar 23, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.47M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 5, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($319.07M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($291.01M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($262.67M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($231.64M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($181.90M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($130.21M) | Mar 23, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $54.96M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $51.60M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $50.76M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $62.00M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $136.00M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $55.70M | Mar 23, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2021 | $10.00M | Mar 16, 2023 |
| FY2022 | Dec 31, 2020 | $10.00M | Mar 16, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 13, 2025 |
| FY2021 | Dec 31, 2021 | (2) | Mar 23, 2022 |
| FY2022 | Dec 31, 2020 | (3) | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | (3) | Mar 23, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 13, 2025 |
| FY2021 | Dec 31, 2021 | (2) | Mar 23, 2022 |
| FY2022 | Dec 31, 2020 | (3) | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | (3) | Mar 23, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 78.35M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 73.23M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | 70.12M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 65.74M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | 64.32M | Mar 16, 2023 |
| FY2023 | Nov 15, 2021 | 500.00M | Mar 13, 2024 |
| FY2021 | Dec 31, 2020 | 11.88M | Mar 23, 2022 |